Skip to main content
Fig. 2 | EJNMMI Research

Fig. 2

From: The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases

Fig. 2

Timing for 17G1 imaging and pharmacokinetics. The radiotracer (111In-17G1) was injected as described in the “Methods” section. A first SPECT/CT imaging of the prostate was performed after 48 h and then daily for two more days (top panel). Lesion-to-background ratio was determined and plotted (top panel). Blood was sampled from prior to and over time post-injection till 10 days and processed to determine the plasma concentration of 17G1 as mentioned in the “Methods” section, plotted as the logarithmic 17G1 concentration vs. time (lower panel) and fitted to a straight line (R 2 = 0.99) to calculate the half-life elimination

Back to article page